

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/022466 A1

(51) International Patent Classification:

C07K 14/05 (2006.01) C12N 5/10 (2006.01)
C12N 15/38 (2006.01) A61K 48/00 (2006.01)
C12N 15/85 (2006.01)

(21) International Application Number:

PCT/CN2023/109708

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/109012
29 July 2022 (29.07.2022) CN

(71) Applicant (for CN only): **WUXI BIOLOGICS (SHANGHAI) CO., LTD.** [CN/CN]; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(71) Applicant (for all designated States except CN): **WUXI BIOLOGICS IRELAND LIMITED** [IE/IE]; Mullagharlin, Dundalk, Co Louth, A91 X56f (IE).

(72) Inventors: **LIAO, Shanhui**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **LU, Huihui**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **GUO, Qian**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CHEN, Xiaoyue**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **CAI, Jiexing**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN). **ZHOU, Weichang**; No. 299 Fute Zhong Road, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC**; 435 Guiping Road, Xuhui District, Shanghai 200233 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FUNCTION-ENHANCED ENGINEERED EBNA1 FOR PROTEIN EXPRESSION IN MAMMALIAN CELLS

(57) Abstract: Provided herein are engineered Epstein-Barr virus nuclear antigen 1 (EBNA1), coding molecules thereof, vectors and mammalian cell expression systems comprising the same, and polypeptide of interest recombinantly produced by the foregoing. Also provided are methods for the preparation of the engineered EBNA1s, coding molecules thereof, vectors and mammalian cell expression systems and methods for using the same in recombinant expression.

WO 2024/022466 A1